Home » Stocks » Genprex

Genprex, Inc. (GNPX)

Stock Price: $3.15 USD -0.03 (-0.94%)
Updated Jul 9, 2020 8:39 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 121.68M
Revenue (ttm) n/a
Net Income (ttm) -14.06M
Shares Out 38.63M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $3.15
Previous Close $3.18
Change ($) -0.03
Change (%) -0.94%
Day's Open 3.18
Day's Range 3.07 - 3.32
Day's Volume 49,132
52-Week Range 0.23 - 7.03

More Stats

Market Cap 121.68M
Enterprise Value 98.60M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.63M
Float 26.78M
EPS (basic) -0.72
EPS (diluted) -0.73
FCF / Share -0.38
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.25M
Short Ratio 1.85
Short % of Float 9.52%
Beta -1.01
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.08
Revenue n/a
Operating Income -14.09M
Net Income -14.06M
Free Cash Flow -10.72M
Net Cash 23.08M
Net Cash / Share 0.60
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -54.83%
ROE -90.18%
ROIC -3,085.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$6.50*
(106.35% upside)
Low
5.00
Current: 3.15
High
8.00
Target: 6.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-----
Operating Income-10.68-12.36-3.31-4.13-1.07
Net Income-10.65-12.37-3.31-4.13-1.07
Shares Outstanding16.0313.7711.5010.831.87
Earnings Per Share-0.66-0.90-0.29-0.38-0.57
Operating Cash Flow-6.92-6.85-2.17-1.25-0.69
Capital Expenditures-0.84-0.02-0.01--
Free Cash Flow-7.75-6.87-2.18-1.25-0.69
Cash & Equivalents2.008.600.161.600.24
Net Cash / Debt2.008.600.161.600.24
Assets3.539.271.261.910.41
Liabilities0.510.390.830.290.02
Book Value3.028.880.431.620.39
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Genprex, Inc.
Country United States
Employees 8
CEO J. Rodney Varner

Stock Information

Ticker Symbol GNPX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GNPX
IPO Date March 29, 2018

Description

Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company's lead product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex also block mechanisms that create drug resistance. The company was founded in 2009 and is headquartered in Austin, Texas.